BEERSE, Belgium--(BUSINESS WIRE)--Data from the investigational, randomised, multi-centre, open-label Phase 3 RESONATETM-2 (PCYC-1115) trial show ibrutinib (IMBRUVICA®) was superior to chlorambucil in all efficacy endpoints measured in patients with treatment-na"ive chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) aged 65 or older, Janssen-Cilag International NV announced today. Kamagra (Sildenafil Citrate) without prescription Ibrutinib significantly prolonged progression-free survival (PFS), the study’s primary endpoint, and overall survival (OS), a key secondary endpoint, and also improved other haematologic measures. Buy Neggram (Nalidixic Acid) with no prescription Notably, ibrutinib was associated with a 98 percent OS rate versus 85 percent for chlorambucil at 24 months. Proventil (Albuterol) without prescription These data will be included in a presentation today during the official press programme at the 2015 American Society of Hematology (ASH) meeting in Orlando, FL, U.S. Buy Infiniair with free prescription and simultaneously published in The New England Journal of Medicine.1 IMBRUVICA is co-developed by Cilag GmbH International, a member of the Janssen Pharmaceutical Companies, and Pharmacyclics LLC, an AbbVie company. Caverta (Sildenafil Citrate) with no prescription Janssen affiliates market IMBRUVICA in EMEA (Europe, Middle East and Africa) as well as the rest of the world, except for the United States, where Janssen Biotech, Inc. Buy Histidine online and Pharmacyclics LLC co-market it. These data will be presented in full by RESONATE-2 study investigator Alessandra Tedeschi, M.D., Medical Director, Azienda Ospedaliera Niguarda Ca Granda, Milan, Italy, during the “CLL: Therapy, Excluding Transplantation: Upfront CLL Therapy Excluding Transplantation” session on Monday, December 7, at 7:30am Eastern Time (ET) / 1.30pm Central European Time (CET). "The RESONATE-2 trial is ground-breaking as the first randomised Phase 3 trial of B-cell receptor antagonist, ibrutinib, in previously untreated CLL,” said Professor Peter Hillmen, Haematology, St. http://doctor-consult.blogspot.com James’s University Hospital, Leeds, who is an investigator in the RESONATE-2 clinical trial. “The results of RESONATE-2 are impressive. The improvement in progression free survival for ibrutinib in front-line treatment compared to chlorambucil is statistically significant. The improvement in overall survival for ibrutinib compared to chlorambucil even with a pre-planned cross-over to ibrutinib is unexpected. This indicates that the best outcomes will be achieved with ibrutinib when it is used as the initial therapy in patients with CLL." The Independent Review Committee (IRC) found ibrutinib significantly prolonged PFS compared with chlorambucil. The hazard ratio (HR) was 0.16 (95 percent CI, 0.09-0.28; P<0.001), which represents a reduction in the risk of progression or death by 84 percent versus chlorambucil (median not reached vs. 18.9 months); the PFS rate at 18 months was 90 percent for ibrutinib versus 52 percent for chlorambucil. Ibrutinib also significantly prolonged OS (HR=0.16: 95 percent CI, 0.05, 0.56; P=0.001) with a 24-month survival rate of 98 percent, compared to 85 percent for patients in the chlorambucil arm. Additionally, ibrutinib was associated with a significantly higher ORR (86 percent vs. 35 percent; P<0.001) as assessed by the IRC and significantly increased the rate of sustained improvements in both haemoglobin and platelets.1 “RESONATE-2 is the first Phase 3 head-to-head trial to evaluate the efficacy and safety of ibrutinib monotherapy versus traditional chemotherapy in patients with treatment-na"ive CLL. The strength of these data may very well represent a turning point in the treatment of CLL/SLL and change when it may be appropriate to treat these patients with ibrutinib,” said Jane Griffiths, Company Group Chairman, Janssen Europe, Middle East and Africa. “We continue to see positive results with ibrutinib, and it is particularly exciting to see the extent of new data at ASH, demonstrating our commitment to exploring ibrutinib use for those who could most benefit from it, and our growing haematology offering.” The safety of ibrutinib in this patient population was consistent with previously reported studies. It is worth noting that exposure to treatment and adverse event (AE) follow-up was nearly 2.5 times longer for ibrutinib compared with chlorambucil and 87 percent of patients randomised to ibrutinib were still on therapy at the time of analysis. Overall, AEs leading to treatment discontinuation were less frequent with ibrutinib than with chlorambucil (nine percent vs. 23 percent, respectively). The most common AEs (>=20 percent) of any Grade in the RESONATE-2 trial for ibrutinib were diarrhoea (42 percent), fatigue (30 percent), cough (22 percent) and nausea (22 percent); AEs for chlorambucil included nausea (39 percent), fatigue (38 percent), neutropenia (23 percent) and vomiting (20 percent). Hypertension occurred at a higher rate in the ibrutinib arm (14 percent; Grade 3 in four percent, no Grade 4 or 5). All six patients with Grade 3 hypertension were managed with hypertensive medication and did not require ibrutinib dose reduction or discontinuation. Four ibrutinib patients experienced Grade 3 haemorrhage and one experienced Grade 4 haemorrhage.1 Atrial fibrillation occurred in eight patients (six percent) in the ibrutinib arm and was primarily Grade 2 in six patients and Grade 3 in two patients. It was managed with discontinuation in two patients and without a dose modification in remaining patients. There were three deaths in the ibrutinib arm and 17 deaths on the chlorambucil arm over the median follow-up of 18.4 months. None of the patients who progressed on the ibrutinib arm died during the subsequent follow-up period.1 RESONATE-2 is a Pharmacyclics-sponsored trial and is the second Phase 3 study demonstrating a significant benefit of ibrutinib vs. a comparator.2,3 The trial enrolled 269 patients with CLL/SLL aged 65 years or older without prior treatment in the U.S., EU and other regions. CLL patients with deletion of the short arm of chromosome 17 (del 17p CLL) were excluded from the trial as single-agent chlorambucil is not recognised as an appropriate therapy in this patient population. Patients were randomised to receive either ibrutinib 420 mg orally, once daily until progression or toxicity or chlorambucil 0.5 to 0.8 mg/kg on days one and 15 of each 28-day cycle for up to 12 cycles. The primary endpoint of the study was PFS as assessed by an IRC according to the International Workshop on Chronic Lymphocytic Leukaemia (iWCLL) 2008 criteria, with modification for treatment-related lymphocytosis. Key secondary endpoints included ORR, OS, rate of haematologic improvement and safety.1 The RESONATE-2 results are the basis for a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for IMBRUVICA to include previously untreated patients with CLL, which was which was announced on November 3, 2015. More information about the study can be found on .clinicaltrials.gov. About IMBRUVICA® (ibrutinib) Ibrutinib is a first-in-class Bruton s tyrosine kinase (BTK) inhibitor, which works by forming a strong covalent bond with BTK to block the transmission of cell survival signals within the malignant B cells.4 By blocking this BTK protein, ibrutinib helps kill and reduce the number of cancer cells. It also slows down the worsening of the cancer.5 Ibrutinib is approved in Europe for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line patients with CLL in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy;6 it is also approved for adult patients with Waldenstr"om’s macroglobulinemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy;6 regulatory approval for additional uses has not yet been granted. Investigational uses for ibrutinib, alone and in combination with other treatments, are under way in several blood cancers including CLL, MCL, WM, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), multiple myeloma (MM) and marginal zone lymphoma (MZL). Ibrutinib is co-developed by Cilag GmbH International, a member of the Janssen Pharmaceutical Companies, and Pharmacyclics LLC, an AbbVie company. Janssen affiliates market ibrutinib in EMEA (Europe, Middle East and Africa) as well as the rest of the world, except for the United States, where Janssen Biotech, Inc. and Pharmacyclics LLC co-market it. Janssen and Pharmacyclics are continuing an extensive clinical development programme for ibrutinib, including Phase 3 study commitments in multiple patient populations – please see the IMBRUVICA summary of product characteristics for further information. About CLL In most patients, CLL is generally a slow-growing blood cancer of the white blood cells called B-lymphocytes.7 The median age at diagnosis is 72 years,8 and incidence rates among men and women in Europe are approximately 5.87 and 4.01 cases per 100,000 persons per year, respectively.9 CLL is a chronic disease; median overall survival ranges between 18 months and more than 10 years according to the stage of disease.10 The disease eventually progresses in the majority of patients, and patients are faced with fewer treatment options each time. Patients are often prescribed multiple lines of therapy as they relapse or become resistant to treatments. CLL cells are found in both the lymphatic system and the blood.11 When the cancer cells are located mostly in the lymph nodes, the disease is called small lymphocytic lymphoma (SLL). Both CLL and SLL are considered different manifestations of the same entity, as classified in the fourth edition of the World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues.12 Janssen in Oncology Our goal is to fundamentally alter the way cancer is understood, diagnosed, and managed, reinforcing our commitment to the patients who inspire us. In looking to find innovative ways to address the cancer challenge, our primary efforts focus on several treatment and prevention solutions. These include a focus on haematologic malignancies, prostate cancer and lung cancer; cancer interception with the goal of developing products that interrupt the carcinogenic process; biomarkers that may help guide targeted, individualised use of our therapies; as well as safe and effective identification and treatment of early changes in the tumour microenvironment. About Janssen Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology (e.g., multiple myeloma and prostate cancer), immunology (e.g., psoriasis), neuroscience (e.g., schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS, hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g., diabetes). Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders, based on partnerships of trust and transparency. More information can be found on .janssen-emea.com. Follow us on .twitter.com/janssenEMEA for our latest news. Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of any of the Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in new product development, including obtaining regulatory approvals; uncertainty of commercial success; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behaviour and spending patterns or financial distress of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; manufacturing difficulties and delays; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson s Annual Report on Form 10-K for the fiscal year ended December 28, 2014, including in Exhibit 99 thereto, and the company s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at .sec.gov, .jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertake to update any forward-looking statement as a result of new information or future events or developments. References 1. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib vs chlorambucil in treatment-na"ive chronic lymphocytic leukemia. N Engl J Med. 2015:1-8. 2. Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213-23. 3. Brown JR, Hillmen P, O’Brien S, et al. Updated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 RESONATE™ trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Blood. 2014;124(21):abstract 3331. 4. O’Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15:48-58. 5. European Medicines Agency. How is the medicine expected to work? .ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2012/06/human_orphan_001058.jsp&mid=WC0b01ac058001d12b Last accessed November 2015. 6. Imbruvica Summary of Product Characteristics, October 2015. Available at: .ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003791/WC500177775.pdf Last accessed November 2015. 7. American Cancer Society. What is chronic lymphocytic leukemia? Available at: .cancer.org/cancer/leukemia-chroniclymphocyticcll/detailedguide/leukemia-chronic-lymphocytic-what-is-cll Last accessed November 2015. 8. Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M; ESMO Guidelines Working Group. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22(Suppl.6):vi50-vi54. 9. Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010;116:3724-34. 10. Sagatys EM, Zhang L. Clinical and laboratory prognostic indicators in chronic lymphocytic leukemia. Cancer Control 2012;19:18-25.Stilgenbauer S, Zenz T. Understanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia. Hematology. 2010;481-8. 11. Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline. Blood. 2013;122:3723-34. 12. Santos FP, O’Brien S. Small lymphocytic lymphoma and chronic lymphocytic leukemia are they the same disease? Cancer J. 2012;8:396-403.

. http://webmd-magazine.blogspot.com Buy Golden Seal online About Colospa (Mebeverine) with free Rx About Hytinic Buy Epivir Hbv (Lamivudine) with free Rx Plavix (Clopidogrel) with free prescription Buy Flagyl (Metronidazole) with no Rx

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced that the US Food and Drug Administration’s (FDA) Arthritis Advisory Committee (AAC) voted 10-4 to recommend the approval of lesinurad 200 mg tablets for the treatment of hyperuricemia associated with gout, in combination with a xanthine oxidase inhibitor (XOI). About Depakote (Divalproex) without prescription The AAC reviewed safety and efficacy data from the pivotal Phase III combination therapy program trials, representing the largest clinical trial data set of gout patients treated with combination urate lowering therapy. The FDA is not bound by the Advisory Committee’s recommendation but takes its advice into consideration when reviewing the application for a potential medicine. About Rogaine (Minoxidil) with no Rx The Prescription Drug User Fee Act (PDUFA) target goal date for lesinurad is December 29, 2015. If approved, lesinurad will be the first selective uric acid reabsorption inhibitor, or SURI, in the US. About Astelin (Azelastine) without Rx It inhibits the urate transporter, URAT1, which is responsible for the majority of the renal reabsorption of uric acid. Sean Bohen, Executive Vice President of Global Medicines Development and Chief Medical Officer, AstraZeneca, said: “The Committee’s positive recommendation for lesinurad is an encouraging step for patients suffering from the debilitating effects of gout, a disease in which there has been limited treatment innovation over the last 50 years. About Griseofulvin with free prescription We look forward to the outcome of the FDA’s review and the opportunity to provide a new treatment option that when combined with an XOI addresses both the under-excretion and over-production of uric acid, the underlying causes of gout.” Gout is a serious and debilitating form of inflammatory arthritis caused by hyperuricemia (elevated serum uric acid (sUA)). Buy Dilantin (Phenytoin) with free prescription Gout affects millions of Americans, many of whom do not reach recommended sUA treatment goals on the current standard of care (XOIs), which decrease production of uric acid. Buy Food Based Calcium and Magnesium online For those inadequately controlled patients, the addition of a urate lowering therapy to increase excretion of uric acid, may help them achieve treatment goals. Lesinurad is also under regulatory review in the European Union and other territories. NOTES TO EDITORS About Lesinurad If approved, lesinurad will be the first selective uric acid reabsorption inhibitor, or SURI, in the US. http://webmd-help.blogspot.com It inhibits the urate transporter, URAT1, which is responsible for the majority of the renal reabsorption of uric acid. By inhibiting URAT1, lesinurad increases uric acid excretion and thereby lowers serum uric acid (sUA). Lesinurad also inhibits organic anion transporter (OAT4) a uric acid transporter involved in diuretic-induced hyperuricemia. In addition, in patients, lesinurad does not inhibit OAT1 and OAT3, which are drug transporters in the kidney associated with drug-drug interactions. If approved, lesinurad in combination with an XOI would provide a dual mechanism of action to increase excretion and decrease production of uric acid enabling more patients with inadequately controlled gout to achieve target treatment goals. About Hyperuricemia and Gout Gout is a serious, chronic, progressive, and debilitating form of inflammatory arthritis. Currently, there are more than 8.3 million patients suffering from gout in the US. The underlying cause of gout is hyperuricemia (elevated serum uric acid (sUA)), which leads to the deposition of crystals primarily in the joints and in other tissues. This can result in recurrent attacks of inflammatory arthritis and, if left uncontrolled, could lead to chronic, progressive arthritis, and tophus (visible deposits of urate crystals) formation. The goal of sUA lowering treatment is to reduce sUA levels tothe target level of <6.0 mg/dL as recommended by the American College of Rheumatology (ACR). To improve signs and symptoms such as tophaceous gout, the ACR guidelines state that achieving and maintaining sUA levels <5.0 mg/dL may be required. Among patients treated in clinical trials, less than 50% of patients on allopurinol 300 mg reached serum uric acid (sUA) target levels <6.0 mg/dL. This suggests approximately two million gout patients in the US on urate lowering therapy remain inadequately controlled. For patients who cannot reach target on an XOI alone, the current ACR guidelines recommend adding an agent that increases uric acid excretion. About Ardea Biosciences Ardea Biosciences, Inc. was acquired by AstraZeneca in June 2012. It is located in San Diego, California and is a member of the AstraZeneca Group. Ardea is leading the development of AstraZeneca’s gout portfolio, including lesinurad and RDEA3170. RDEA3170 is a potent selective uric acid reabsorption inhibitor (SURI), also intended for use as a combination urate lowering therapy with xanthine oxidase inhibitors (XOIs). RDEA3170 is our lead investigational urate lowering therapy (ULT) in Asia and is currently entering a Phase IIb trial in the US. About AstraZeneca AstraZeneca (NYSE: AZN) is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: .astrazeneca-us.com. 3176137 10/15

ELLENTON, Fl orida--(BUSINESS WIRE)--A fam ilia Feld, propriet aria da Feld Entertainment, Inc. Buy Cellcept (Mycophenolate Mofetil) with no Rx – empresa matriz do Ringling Bros. About Temovate (Clobetasol) without Rx and Barnum & Bailey® e do Ringling Bros. About Exelon (Rivastigmine Tartrate) Center for Elephant Conservation® –, anunciou ontem um novo esforco de financiamento com o Intermountain Primary Children’s Hospital (PCH), com oncologistas do Departamento de Pediatria da Universidade de Utah e com o Dr. Genpril with free Rx Joshua Schiffman do Huntsman Cancer Institute. Buy Evecare () without prescription O compromisso de captac~ao de recursos vem na sequ^encia de novas descobertas de uma pesquisa sobre c^ancer publicada pelo Dr. Buy Erectile Dysfunction online Schiffman no Journal of American Medical Association (JAMA), o peri odico cient ifico da Associac~ao M edica Americana. A Feld Entertainment lancou hoje um pacote de v ideo de acompanhamento que descreve a pesquisa. http://webmd-review.blogspot.com O v ideo pode ser visto aqui. Dr. Schiffman e a equipe do Primary Children’s Hospital, do Departamento de Pediatria e do Huntsman Cancer Institute – todos situados em Salt Lake City, Utah – est~ao estudando por que h a uma incid^encia t~ao baixa de c^ancer em elefantes, o que torna poss ivel essa resist^encia `a doenca entre elefantes e n~ao em seres humanos, e como isso pode se correlacionar com novos tratamentos de c^ancer pedi atrico. Mais de 16 mil criancas e adolescentes s~ao diagnosticados com c^ancer todos os anos nos Estados Unidos, enquanto entre elefantes, praticamente n~ao h a incid^encia da doenca ao longo de toda a vida do animal. Dr. Schiffman; Dr. Dennis Schmitt, chefe de Servicos Veterin arios e diretor de Pesquisa do Ringling Bros. and Barnum & Bailey; e Dr. Wendy Kiso, cientista de Pesquisa e Conservac~ao do Ringling Bros. Center for Elephant Conservation; entre outros colaboradores cientistas em suas equipes, confirmaram recentemente que os elefantes raramente desenvolvem c^ancer, com uma taxa de mortalidade inferior a 5%. Para efeito de comparac~ao, a mesma taxa entre humanos e de 25%. Ao estudarem o genoma dos elefantes, eles descreveram que esses animais possuem 40 c opias de um gene supressor de tumor chamado TP53, enquanto os seres humanos t^em somente duas c opias. Trabalhando com o Jardim Zool ogico Hogle de Utah e o Ringling Bros. Center for Elephant Conservation, Dr. Schiffman e seus colegas estudaram a reac~ao do sangue de elefantes a agentes de danificac~ao de DNA e descobriram que a c elula do animal sofre morte celular mais rapidamente quando comparada com as celulas humanas. Dr. Schiffman acredita que pode ser por isso que os elefantes desenvolvem menos c^ancer do que os seres humanos. As descobertas completas do estudo foram publicadas na nova edic~ao do Journal of American Medical Association. A aplicac~ao de pesquisa translacional sobre o c^ancer – as descobertas provenientes da ci^encia b asica que melhoram a sa ude e o bem-estar humanos aperfeicoando pr aticas m edicas e de enfermagem, e criando resultados de sa ude significativos – poderia pavimentar o caminho rumo a uma fronteira inteiramente nova para a pesquisa e o tratamento do c^ancer, da mesa do laborat orio ao leito do paciente. A fam ilia Feld est a formando o Ringling Bros. Children’s Fund™ como um elemento de sua filantropia cont inua atrav es da Feld Family Foundation para apoiar iniciativas beneficentes para as criancas. Como parte da parceria com o Primary Children’s Hospital, o Departamento de Pediatria e Dr. Schiffman, o Ringling Bros. Children’s Fund e o Ringling Bros. and Barnum & Bailey ir~ao doar mais de US$ 1 milh~ao em apoio `a pesquisa sobre o c^ancer e ao atendimento de criancas. Nas pr oximas 50 cidades visitadas pelo Ringling Bros. and Barnum & Bailey , a Ringling Bros. ir a doar US$ 10 mil a um hospital infantil ou centro de tratamento local, e o Ringling Bros. Children’s Fund ir a equiparar cada doac~ao com uma doac~ao adicional de US$ 10 mil `a Primary Children’s Hospital Foundation em apoio a seu Programa de Pesquisa sobre o C^ancer Pedi atrico. Esse programa, que ajudou a apoiar a pesquisa com elefantes, concentra-se em novas abordagens de prevenc~ao e diagn ostico, e na melhoria do valor do tratamento contra o c^ancer pedi atrico. Informac~oes adicionais sobre o Ringling Bros. and Barnum & Bailey e o Ringling Bros. Center for Elephant Conservation, a parceria e tamb em sobre como as fam ilias podem fazer doac~oes `a pesquisa podem ser encontradas na internet em .ringling.com e .ringlingelephantcenter.com. NOTA DO EDITOR: Informac~oes complementares para apoiar a reportagem est~ao anexas e podem ser encontradas tamb em aqui. Sobre a Feld Entertainment A Feld Entertainment e a l ider mundial em turn^es de produc~ao e apresentac~ao ao vivo, dedicadas a experi^encias de entretenimento familiar que eleva o esp irito humano e cria mem orias inesquec iveis, com 30 milh~oes de espectadores em suas apresentac~oes a cada ano. As produc~oes da Feld Entertainment j a estiveram at e hoje em mais de 75 pa ises e nos seis continentes e incluem Ringling Bros. and Barnum & Bailey®, Monster Jam®, Monster Energy Supercross, AMSOIL Arenacross, Disney On Ice apresentada por Stonyfield YoKids Organic Yogurt, Disney Live! Apresentada por Stonyfield YoKids Organic Yogurt e Marvel Universe LIVE! Mais informac~oes sobre a Feld Entertainment podem ser encontradas em .feldentertainment.com. Mais informac~oes sobre o Ringling Bros. Center for Elephant Conservation est~ao dispon iveis em .ringlingelephantcenter.com. Sobre o Primary Children’s Hospital O Primary Children s Hospital e o unico hospital infantil de servicos integrais para Utah, Idaho, Wyoming, Nevada e Montana, prestando atendimento a criancas com as mais complexas les~oes e enfermidades, incluindo as que necessitam de transplante de corac~ao, f igado, rim e medula ossea. O Primary Children’s e o unico Centro de Trauma Pedi atrico de N ivel 1 na regi~ao Intermountain West. O hospital e de propriedade da Intermountain Healthcare, um sistema de assist^encia `a sa ude sem fins lucrativos, e e afiliado `a Escola de Medicina da Universidade de Utah, que re une pesquisa, treinamento e tratamento de excel^encia para oferecer a melhor assist^encia `a sa ude para as criancas. As doac~oes s~ao administradas pela Primary Children’s Hospital Foundation, uma instituic~ao beneficente incorporada separadamente sob o c odigo IRS 501(c)(3). A fundac~ao apoia as metas do hospital de oferecer assist^encia pedi atrica do mais alto n ivel em uma atmosfera de amor e cuidado. Sobre o Departamento de Pediatria da Universidade de Utah O Departamento de Pediatria e o segundo maior departamento da Escola de Medicina da Universidade de Utah e um dos maiores departamentos pedi atricos dos EUA. Ele possui mais de 270 membros docentes, com uma distribuic~ao equitativa entre homens e mulheres, e tem o maior n umero de docentes titulares mulheres da Escola de Medicina. O departamento e composto de 22 divis~oes m edicas e programas, que operam em conjunto com quatro iniciativas principais: educac~ao, pesquisa, cl inica e acad^emica. Suas divis~oes fornecem um conjunto completo de especialidades e subespecialidades de servicos pedi atricos para criancas de toda a regi~ao de Intermountain West. Sobre o Huntsman Cancer Institute da Universidade de Utah O Huntsman Cancer Institute (HCI) e um dos maiores centros de pesquisa acad^emica e tratamento de c^ancer do mundo. O HCI gerencia o Banco de Dados da Populac~ao de Utah , a maior base de dados gen etica do mundo, com mais de 16 milh~oes de registros vinculados a genealogias, registros de sa ude e estat isticas vitais. Utilizando esses dados, os pesquisadores do HCI j a identificaram v arios genes causadores de c^ancer, incluindo aqueles respons aveis por melanoma, c^ancer de colo do utero, c^ancer de mama e paraganglioma. O instituto e membro da National Comprehensive Cancer Network (uma alianca composta de 26 centros de c^ancer l ideres mundiais) e e um National Cancer Institute-Designated Comprehensive Cancer Center. O HCI trata pacientes com todas as formas de c^ancer e opera diversas cl inicas de alto risco dedicadas ao c^anceres de pele, mama, colo do utero e p^ancreas. O Centro de Aprendizagem sobre o C^ancer do HCI, voltado `a formac~ao de pacientes e do p ublico em geral, cont em um dos maiores acervos de publicac~oes sobre c^ancer dos EUA. O nome do instituto e uma homenagem a Jon M. Huntsman, um filantropo, industrial e sobrevivente do c^ancer de Utah. O texto no idioma original deste an uncio e a vers~ao oficial autorizada. As traduc~oes s~ao fornecidas apenas como uma facilidade e devem se referir ao texto no idioma original, que e a unica vers~ao do texto que tem efeito legal.

. Buy Detox online Fosamax without prescription Viagra Strips (Sildenafil Citrate) without Rx NEW YORK--(BUSINESS WIRE)--Replicor maakt bekend dat de rekrutering van pati"enten is begonnen voor de tweede fase II studie bij blanke pati"enten waaruit de veiligheid en antivirale werkzaamheid van REP 2139-Mg of REP 2165-Mg in combinatie met Viread® en Pegasys® of Zadaxin® bij pati"enten met HBeAg-negatieve chronische hepatitis B infectie moet blijken. Het ontwerp van het REP 401 protocol (NCT02565719) is gebaseerd op de ervaringen van Replicor met REP 2055 en REP 2139-Ca van zijn vorige vier fase II studies bij Aziatische en blanke pati"enten met een HBV of HBV/HDV-infectie. Deze bekendmaking is officieel geldend in de originele brontaal. http://pharmaceutical-journal.blogspot.com About Green Coffee () without prescription Fulvicin (Gresiofulvin) without Rx Buy Avalide (Irbesartan Hydrochlorothiazide) without Rx Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, welke als enige rechtsgeldig is.

KENILWORTH, N.J.--(BUSINESS WIRE)--MSD, known as Merck (NYSE:MRK) in the United States and Canada, today announced the first-time presentation of findings investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, as a monotherapy in patients with advanced unresectable nasopharyngeal carcinoma (NPC) – a type of head and neck cancer – whose tumors express PD-L1 (>=1% of cells in tumor nests or PD-L1+ bands in stroma). Actoplus Met (Metformin And Pioglitazone) with no prescription Data were from a Phase 1b study (KEYNOTE-028) and showed an overall response rate (ORR) (confirmed and unconfirmed) of 22.2 percent (95% CI, 8.6-42.3) in evaluable patients (n=27) who were treated with KEYTRUDA. Zocor (Simvastatin) with free prescription Results were presented in an oral session by Dr. Cialis Strong Pack-30 () without prescription Chiun Hsu, National Taiwan University Hospital, at the European Cancer Congress (ECC) in Vienna (Abstract #2801). “Advanced nasopharyngeal carcinoma is a severe form of head and neck cancer often associated with a poor prognosis,” said Dr. About Fluoromethalone without Rx Hsu. Kamagra Effervescent (Sildenafil Citrate) “These data presented at ECC represent the potential for new approaches to treat this type of cancer, for which there are currently limited treatment options, and further support the need for additional research into how KEYTRUDA may work for certain types of head and neck cancer.” MSD has initiated a comprehensive clinical development program evaluating KEYTRUDA in head and neck cancer across multiple lines of therapy as monotherapy and in combination with chemotherapy as well as other agents. Buy Cold Formulas online In KEYNOTE-028, KEYTRUDA is being evaluated in patients with advanced unresectable NPC that is not responding to current therapy or for which current therapy is not appropriate. http://webmd-consult.blogspot.com This is the second study to show early activity of KEYTRUDA in patients with head and neck cancer and the first study of an anti-PD-1 therapy to demonstrate clinical activity in patients with recurrent or metastatic NPC. For more information about our oncology clinical trials, visit .keynoteclinicaltrials.com. “The findings emerging from this trial again demonstrate that KEYTRUDA is active across a broad range of cancers, including those that are difficult to treat with standard treatments,” said Dr. Roger Dansey, senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories. “Based on these and other results to date, we are continuing to advance a comprehensive head and neck clinical program for KEYTRUDA, and we remain focused on realizing its full potential to address the unmet treatment needs for patients with difficult-to-treat cancers such as nasopharyngeal carcinoma.” Additional Nasopharyngeal Carcinoma Results from KEYNOTE-028 KEYNOTE-028 is an ongoing multi-cohort, non-randomized Phase 1b basket trial (a trial design that allows for the study of multiple sub-populations of different tumor or histological types within one study) evaluating the safety, tolerability, and anti-tumor activity of KEYTRUDA monotherapy (10 mg/kg dosed every two weeks) in more than 450 patients across 20 different types of cancer. The study was designed to evaluate patients with advanced solid tumors that express PD-L1 and which have not responded to current therapy or for which current therapy is not appropriate. These early findings from 27 heavily pre-treated patients with advanced NPC demonstrated an ORR of 22.2 percent (n=6/27) (per RECIST v1.1), including six partial responses (95% CI, 8.6-42.3). Additionally, 55.6 percent of patients had stable disease (n=15/27) (95% CI, 35.3-74.5), the disease control rate (DCR) was 77.8 percent (n=21/27) (95% CI, 57.7-91.4), and tumor shrinkage was achieved in 67 percent of patients. The 6-month progression-free survival (PFS) rate was 49.7 percent and the 12-month PFS rate was 28.9 percent. The median follow-up duration for evaluable patients was 12.9 months (range, 2.2-15.0) and the median response duration was 10.8 months (range, 4.8- 10.8). Adverse events were generally consistent with previously reported safety data for KEYTRUDA. Grade 3-5 investigator-assessed, treatment-related adverse events were hepatitis (n=2), pneumonitis (n=2), anemia (n=1), facial pain (n=1), increased blood creatine phosphokinase (n=1), proteinuria (n=1), and sepsis (n=1). Immune-mediated adverse events were hypothyroidism (n=5), hepatitis (n=4), and pneumonitis (n=3). There was one treatment-related death due to bacterial sepsis. About PD-L1 and PD-L1 Expression PD-L1, also called programmed death-ligand 1, is a protein expressed on many types of cells, including some cancer cells. Under normal conditions, the interaction of PD-L1 with another protein, called programmed death receptor-1 (PD-1), serves as an important immune system checkpoint, keeping the immune system in balance and preventing the body from attacking its own cells when inflammation or an infection is present. When cancerous tumors express PD-L1, however, they are able to escape detection and destruction by cytotoxic T-cells – a type of cancer-killing immune cell – allowing the tumor to survive and grow. Tumor PD-L1 expression has been observed at varying levels across many tumor types, including breast, lung, bladder cancer, and nasopharyngeal carcinoma. High levels of PD-L1 expression, called overexpression, are under investigation for potential use as a way to help identify patients with an enhanced likelihood to respond to certain immune-based treatment approaches. About Nasopharyngeal Cancer Nasopharyngeal cancer (NPC) is a type of head and neck cancer that starts in the epithelial cells that line the surface of the nasopharynx, the upper part of the throat behind the nose and near the base of skull.1 There are three types of NPC, based on how the cancer cells look under the microscope: keratinizing squamous cell carcinoma, non-keratinizing differentiated carcinoma, and undifferentiated carcinoma.1 Leading risk factors for NPC include Chinese or Asian ancestry, being exposed to the Epstein-Barr virus, and drinking large amounts of alcohol.2 In most parts of the world (including the United States), there is less than one case of NPC for every 100,000 people each year.3 In 2015, about 3,200 cases of NPC are expected to occur in the United States.3 About KEYTRUDA® (pembrolizumab) KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. By binding to the PD-1 receptor and blocking the interaction with the receptor ligands, KEYTRUDA releases the PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The KEYTRUDA clinical development program has rapidly expanded to encompass more than 30 tumor types in more than 130 clinical trials, of which more than 70 trials combine KEYTRUDA with other cancer treatments. Registration-enabling trials of KEYTRUDA monotherapy are currently enrolling patients in melanoma, NSCLC, head and neck cancer, bladder cancer, gastric cancer, colorectal cancer, and Hodgkin Lymphoma, with further trials in planning for other cancers. Selected Important Safety Information for KEYTRUDA Pneumonitis occurred in 12 (2.9%) of 411 patients, including Grade 2 or 3 cases in 8 (1.9%) and 1 (0.2%) patients, respectively, receiving KEYTRUDA. Monitor patients for signs and symptoms of pneumonitis. Evaluate suspected pneumonitis with radiographic imaging. Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 pneumonitis. Colitis (including microscopic colitis) occurred in 4 (1%) of 411 patients, including Grade 2 or 3 cases in 1 (0.2%) and 2 (0.5%) patients, respectively, receiving KEYTRUDA. Monitor patients for signs and symptoms of colitis. Administer corticosteroids for Grade 2 or greater colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for Grade 4 colitis. Hepatitis (including autoimmune hepatitis) occurred in 2 (0.5%) of 411 patients, including a Grade 4 case in 1 (0.2%) patient, receiving KEYTRUDA. Monitor patients for changes in liver function. Administer corticosteroids for Grade 2 or greater hepatitis and, based on severity of liver enzyme elevations, withhold or discontinue KEYTRUDA. Hypophysitis occurred in 2 (0.5%) of 411 patients, including a Grade 2 case in 1 and a Grade 4 case in 1 (0.2% each) patient, receiving KEYTRUDA. Monitor patients for signs and symptoms of hypophysitis (including hypopituitarism and adrenal insufficiency). Administer corticosteroids for Grade 2 or greater hypophysitis. Withhold KEYTRUDA for Grade 2; withhold or discontinue for Grade 3; and permanently discontinue KEYTRUDA for Grade 4 hypophysitis. Hyperthyroidism occurred in 5 (1.2%) of 411 patients, including Grade 2 or 3 cases in 2 (0.5%) and 1 (0.2%) patients, respectively, receiving KEYTRUDA. Hypothyroidism occurred in 34 (8.3%) of 411 patients, including a Grade 3 case in 1 (0.2%) patient, receiving KEYTRUDA. Thyroid disorders can occur at any time during treatment. Monitor patients for changes in thyroid function (at the start of treatment, periodically during treatment, and as indicated based on clinical evaluation) and for clinical signs and symptoms of thyroid disorders. Administer corticosteroids for Grade 3 or greater hyperthyroidism. Withhold KEYTRUDA for Grade 3; permanently discontinue KEYTRUDA for Grade 4 hyperthyroidism. Isolated hypothyroidism may be managed with replacement therapy without treatment interruption and without corticosteroids. Type 1 diabetes mellitus, including diabetic ketoacidosis, has occurred in patients receiving KEYTRUDA. Monitor patients for hyperglycemia and other signs and symptoms of diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA in cases of severe hyperglycemia until metabolic control is achieved. Nephritis occurred in 3 (0.7%) patients, consisting of one case of Grade 2 autoimmune nephritis (0.2%) and two cases of interstitial nephritis with renal failure (0.5%), one Grade 3 and one Grade 4. Monitor patients for changes in renal function. Administer corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis. Other clinically important immune-mediated adverse reactions can occur. The following clinically significant immune-mediated adverse reactions occurred in patients treated with KEYTRUDA: exfoliative dermatitis, uveitis, arthritis, myositis, pancreatitis, hemolytic anemia, partial seizures arising in a patient with inflammatory foci in brain parenchyma, severe dermatitis including bullous pemphigoid, myasthenic syndrome, optic neuritis, and rhabdomyolysis. For suspected immune-mediated adverse reactions, ensure adequate evaluation to confirm etiology or exclude other causes. Based on the severity of the adverse reaction, withhold KEYTRUDA and administer corticosteroids. Upon improvement of the adverse reaction to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Restart KEYTRUDA if the adverse reaction remains at Grade 1 or less. Permanently discontinue KEYTRUDA for any severe or Grade 3 immune-mediated adverse reaction that recurs and for any life-threatening immune-mediated adverse reaction. Infusion-related reactions, including severe and life-threatening reactions, have occurred in patients receiving KEYTRUDA. Monitor patients for signs and symptoms of infusion-related reactions including rigors, chills, wheezing, pruritus, flushing, rashC hypotension, hypoxemia, and fever. For severe or life-threatening reactions, stop infusion and permanently discontinue KEYTRUDA. Based on its mechanism of action, KEYTRUDA may cause fetal harm when administered to a pregnant woman. If used during pregnancy, or if the patient becomes pregnant during treatment, apprise the patient of the potential hazard to a fetus. Advise females of reproductive potential to use highly effective contraception during treatment and for 4 months after the last dose of KEYTRUDA. KEYTRUDA was discontinued for adverse reactions in 9% of 411 patients. Adverse reactions, reported in at least two patients, that led to discontinuation of KEYTRUDA were: pneumonitis, renal failure, and pain. Serious adverse reactions occurred in 36% of patients. The most frequent serious adverse reactions, reported in 2% or more of patients, were renal failure, dyspnea, pneumonia, and cellulitis. The most common adverse reactions (reported in at least 20% of patients) were fatigue (47%), cough (30%), nausea (30%), pruritus (30%), rash (29%), decreased appetite (26%), constipation (21%), arthralgia (20%), and diarrhea (20%). The recommended dose of KEYTRUDA is 2 mg/kg administered as an intravenous infusion over 30 minutes every three weeks until disease progression or unacceptable toxicity. No formal pharmacokinetic drug interaction studies have been conducted with KEYTRUDA. It is not known whether KEYTRUDA is excreted in human milk. Because many drugs are excreted in human milk, instruct women to discontinue nursing during treatment with KEYTRUDA. Safety and effectiveness of KEYTRUDA have not been established in pediatric patients. Our Focus on Cancer Our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. At MSD Oncology, helping people fight cancer is our passion and supporting accessibility to our cancer medicines is our commitment. Our focus is on pursuing research in immuno-oncology and we are accelerating every step in the journey – from lab to clinic – to potentially bring new hope to people with cancer. For more information about our oncology clinical trials, visit .merck.com/clinicaltrials. About MSD Today’s MSD is a global healthcare leader working to help the world be well. MSD is a tradename of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (.sec.gov). References     1.   .cancer.org/cancer/nasopharyngealcancer/detailedguide/nasopharyngeal-cancer-what-is-nasopharyngeal-cancer 2. .cancer.gov/types/head-and-neck/patient/nasopharyngeal-treatment-pdq 3. .cancer.org/cancer/nasopharyngealcancer/detailedguide/nasopharyngeal-cancer-key-statistics

DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/xffzmh/drug_delivery_in) has announced the addition of Jain PharmaBiotech s new report "Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies" to their offering. Advances in understanding of the cell biology of the BBB have opened new avenues and possibilities for improved drug delivery to the CNS. Buy Urispas (Flavoxate) without prescription Several carrier or transport systems, enzymes, and receptors that control the penetration of molecules have been identified in the BBB endothelium. About Cleocin (Clindamycin) with free prescription Receptor-mediated transcytosis can transport peptides and proteins across the BBB. Benemid (Probenecid) with free prescription Methods are available to assess the BBB permeability of drugs at the discovery stage to avoid development of drugs that fail to reach their target site of action in the CNS. Many of the new developments in the treatment of neurological disorders will be biological therapies and these will require innovative methods for delivery. About Estrace without Rx Cell, gene and antisense therapies are not only innovative treatments for CNS disorders but also involve sophisticated delivery methods. About Pamelor (Nortriptyline) RNA interference (RNAi) as a form of antisense therapy is also described. The role of drug delivery is depicted in the background of various therapies for neurological diseases including drugs in development and the role of special delivery preparations. Buy Body Lotion online Pain is included as it is considered to be a neurological disorder. http://anti-infectives-opinion.blogspot.com A special chapter is devoted to drug delivery for brain tumors. Cell and gene therapies will play an important role in the treatment of neurological disorders in the future. The method of delivery of a drug to the CNS has an impact on the drug s commercial potential. The market for CNS drug delivery technologies is directly linked to the CNS drug market. Values are calculated for the total CNS market and the share of drug delivery technologies. Starting with the market values for the year 2014, projections are made to the years 2019 and 2024. The markets values are tabulated according to therapeutic areas, technologies and geographical areas. Unmet needs for further development in CNS drug delivery technologies are identified according to the important methods of delivery of therapeutic substances to the CNS. Finally suggestions are made for strategies to expand CNS delivery markets. Besides development of new products, these include application of innovative methods of delivery to older drugs to improve their action and extend their patent life. Profiles of 76 companies involved in drug delivery for CNS disorders are presented along with their technologies, products and 80 collaborations. These include pharmaceutical companies that develop CNS drugs and biotechnology companies that provide technologies for drug delivery. A number of cell and gene therapy companies with products in development for CNS disorders are included. References contains over 420 publications that are cited in the report. The report is supplemented with 51 tables and 12 figures. Key Topics Covered: Executive Summary 1. Basics of Drug Delivery to the Central Nervous System 2. Blood Brain Barrier 3. Methods of Drug Delivery to the CNS 4. Delivery of Cell, Gene and Antisense Therapies to the CNS 5. Drug Delivery for Treatment of Neurological Disorders 6. Drug delivery for brain tumors 7. Markets for Drug Delivery in CNS Disorders 8. Companies 9. References For more information visit .researchandmarkets.com/research/xffzmh/drug_delivery_in Source: Jain PharmaBiotech

DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/k7pp7t/analysis_of_the) has announced the addition of the "Analysis of the Immunochemistry Market in Malaysia" report to their offering. The Malaysian immunochemistry market is dominated by Roche, Siemens, and Beckman Coulter. Buy Singulair (Montelukast) with no Rx Other participants are Becton Dickenson, Abbott, Sysmex, and some Chinese companies. About Dilantin (Phenytoin) with free Rx The demand for immunochemistry tests in tertiary care hospitals is high. Buy Minomycin (Minocycline) with free prescription Automated equipment is preferred but some tier I and II hospitals operate on semi-automated chemistry analyzers. Enalapril Public hospitals procure equipment using tenders, while reagents are purchased in batches 2-3 times a year. Prometrium (Progesterone) The demand for immunochemistry tests will grow, as communicable disease testing has increased and preventive tests are common. Key Topics Covered: 1. Buy Back Pain Relief online Executive Summary - Scope and Segmentation 2. http://allergy-opinion.blogspot.com Key Trends - Key Companies to Watch - Roche - Key Companies to Watch - Axon Scientific - Key Companies to Watch - BP Healthcare - Key Companies to Watch - Snibe 3. Overview of the Malaysian Healthcare Market - Overview of Healthcare Expenditure in Malaysia - Overview of Population Forecast in Malaysia - Growing Demand for and Affordability of Quality Healthcare Services - Growth in Malaysian Hospitals - Parallel Public and Private Healthcare Sectors in Malaysia - Classification of Healthcare Services (HCS) in Malaysia - Access to Public Secondary and Tertiary Service Care - Principal Cause of Death in Public Hospitals - Principal Cause of Death in Private Hospitals 4. Overview of the Malaysian Hospital Market and Trends in the Immunochemistry Testing Market - Malaysian Hospitals - Market Overview - Category High Public Hospitals (>650 Beds per Hospital) - Key States - Category Medium Public Hospitals (150-650 Beds) - Key States - Category Low Public Hospitals (< 150 Beds) - Key States - Malaysian IVD Market - Market Segmentation - Customer Segmentation in the Malaysian Immunochemistry Market - Segmentation of Key Immunochemistry Tests in Public Hospitals - Type of Tests - Top 3 Immunochemistry Tests in Demand in Malaysian Hospitals - Usage Pattern of Immunochemistry Equipment - In spite of prices of Healthcare services will get impacted due to GST, the volume of test is unlikely to be effected - Demand for Automated Immunochemistry Equipment Versus Conventional End User s Perspective - Procurement Process of Immunochemistry Equipment in Public Hospitals - Procurement Process of Immunochemistry Equipment in Private Hospitals and Diagnostic Laboratories 5. Competitor Playbook - Overview of Key Competitors in the Immunochemistry Market in Malaysia - Revenue Forecast - Demand for Immunochemistry Equipment in Malaysia - A Distributor s Perspective - Top 3 Competitors - Manufacturers - Segment Analysis of Competitors in the Immunochemistry Market - Key Distributors in the Malaysian Immunochemistry Market 6. Opportunities, Drivers, and Restraints in the Malaysian Immunochemistry Market - Opportunity for Automated Equipment Manufacturers - New Public Hospitals in Malaysia - New Private Hospitals in Malaysia - Key Market Drivers - Key Market Restraints 7. Future Trends in the Malaysian Immunochemistry Market For more information visit .researchandmarkets.com/research/k7pp7t/analysis_of_the

Global Sports Medicine Market (by Segment) and Company Analysis to 2020

DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/rwd7br/global_sports) has announced the addition of the "Global Sports Medicine Market (By Segment) and Company Analysis to 2020" report to their offering. The global sports medicine market has been continuously rising over the year and has a rosy future ahead. About Revia (Naltrexone) without Rx Sports medicine focuses on helping people improve their athletic performance, recover from injury and prevent future injuries. About Enablex (Darifenacin) with free Rx It is a fast-growing health care field, because health workers who specialize in sports medicine help many regular people as well as athletes. About Tinidazole () with free Rx The major driving factors for the sports medicine market are the aging population, increasing participation in sports activities, technological advancements in the field of sports medicine, rising awareness among athletes regarding physical and health fitness and the increased incidence of sport related injuries to the athletes and the long recovery periods involved as a cause of the injury. About Elavil The lack of favorable reimbursement policies to the sport related injuries and the high cost of sports medicine has been a major challenge faced by the sports medicine market. Global Sports Medicine Market Segment Wise Analysis: In the Global sports medicine, Shoulder injuries accounts for the maximum share of the market. Buy Retrovir (Zidovudine) The Knee injuries is the second leading segment in 2014 being followed by Mechanical Resection. Buy Appetite Suppressant online Access stands at the fourth spot while RF Resection is holding the fifth spot in the global sports medicine market. Global Sports Medicine Revenue Company Wise Analysis: Arthrex is the global leader in the sports medicine market with Smith & Nephew in the second position. http://asthmareview.wordpress.com DePuy Synthes Mitek holds the third spot in the global sports medicine market. Stryker is the fourth leading player in global sports medicine market in 2014. ConMed Linvatec and Biomet are competing closely with each other in order to grab maximum share of the pie. The Sports Medicine Market covered in the report is analyzed from 2 viewpoints follows: 1. Joint Repair - 3 Segments Covered 1. Hip 2. Knee 3. Shoulder 2. Arthroscopic Enabling Technologies - 5 Segments Covered 1. Video 2. Access 3. RF Resection 4. Mechanical Resection 5. Others The 8 Companies analyzed in the reports are: 1. Arthrex 2. Arthrocare 3. Biomet (Acquired by Zimmer) 4. DePuy Mitek 5. ConMed Linvatec 6. Smith & Nephew 7. Stryker 8. Others Key Topics Covered: 1. Executive Summary 2. Global Sports Medicine Market & Forecast (2012 - 2020) 3. Global Sports Medicine Market Share & Forecast - Segment Wise (2012 - 2020) 4. Global Sports Medicine Market Share & Forecast - Company Wise (2012 - 2020) 5. Global Sports Medicine Market & Forecast - Segment Wise (2012 - 2020) 6. Global Sports Medicine Revenue & Forecast - Company Wise (2012 - 2020) 7. Global Sports Medicine Market - Major Deals 8. Global Sports Medicine Market - Driving Factors 9. Global Sports Medicine Market - Challenges For more information visit .researchandmarkets.com/research/rwd7br/global_sports

DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/qn2tn9/investigation) has announced the addition of the "Investigation Report on China s Polyene Phosphatidyl Choline Market, 2010-2019" report to their offering. China is recognized worldwide as one of the countries with a high incidence of liver disease. Buy Norlutate (Norethindrone Acetate) with free prescription Viral hepatitis, fatty liver, alcoholic liver disease, medicamentous liver lesion and liver cancer have posed a severe threat to the Chinese people s health. Buy Janumet (Sitagliptin Metformin) with no prescription In recent years, drugs for liver disease that rank second to proton pump inhibitor in drugs for the digestive system have gradually become a variety with large sales value which occupies 30% of the total sales value of all ten categories of drugs for digestive system. Among all the drugs for liver disease, polyene phosphatidyl choline is the natural diglyceride of cholinephosphoric acid and unsaturated fatty acids which can protect hepatocyte from lesion, alleviate inflammation reaction and improve the detoxification of the liver. Ovral (Ethinyl estradiol / Norgestrel) with free Rx And it is used for the treatment of hepatitis (acute and chronic), hepatic cirrhosis and poisoning with certain efficacy in the clinic. Buy Dothiepin with free prescription First developed by Sanofi, polyene phosphatidyl choline has been marketed under the trade name of Essentiale Forte. Some local enterprises are already capable of producing polyene phosphatidyl choline APIs and injections. Sustiva (Efavirenz) with no Rx For example, Sichuan Haisco Pharmaceutical Co., Ltd and Chengdu Tiantaishan Pharmaceutical Co., Ltd have been approved to produce polyene phosphatidyl choline under the trade name of Yibisheng. Buy Weight Gainers online Imported drugs mainly come from Sanofi (Beijing), Shenzhen Sanofi Pasteur Biological Products Co., Ltd, Sanofi-Aventis Ukraine LLc and A.Nattermann & Cie.GmbH. The growth of polyene phosphatidyl choline has accelerated since 2006, making it occupy an important proportion of the adjuvant drugs for liver disease. http://medicalhelper.wordpress.com According to this survey, the sales value of polyene phosphatidyl choline in sample hospitals rose from less than CNY 60 million in 2005 to over CNY 400 million in 2014 and CAGR during this period reached 25%. With the lifestyle changes brought about by economic development, the incidence of liver disease in China has kept increasing. Therefore, the market size of polyene phosphatidyl choline is expected to continue to grow in the next few years in China. Key Topics Covered: 1 Related Concepts of Polyene Phosphatidyl Choline 2 Market Profile of Polyene Phosphatidyl Choline in China 3 Survey on Sales Status of Polyene Phosphatidyl Choline in China, 2010-2014 4 Survey on Market Share of Major Manufacturers of Polyene Phosphatidyl Choline in China, 2010-2014 5 Survey on Dosage Forms of Polyene Phosphatidyl Choline in China, 2010-2014 6 Reference Price of Polyene Phosphatidyl Choline in Chinese Hospitals in 2014 7 Major Manufacturers of Polyene Phosphatidyl Choline in Chinese Market, 2010-2014 8 Market Outlook of Polyene Phosphatidyl Choline in China, 2015-2019 Companies Mentioned - Shenzhen Sanofi Pasteur Biological Products Co., Ltd - Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd - Chengdu Tiantaishan Pharmaceutical Co., Ltd - Aventis Pharma S.p.A. For more information visit .researchandmarkets.com/research/qn2tn9/investigation

DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/p8l4hh/global_colorectal) has announced the addition of the "Global Colorectal Cancer Drugs Market 2015-2019" report to their offering. The global colorectal cancer drugs market to grow at a CAGR of 3.62% over the period 2014-2019. Biologics are rapidly becoming the treatment of choice for colorectal cancer. Buy Mobic (Meloxicam) without Rx Biologics are targeted therapy, which act only on the malignant cells and do not attack the healthy cells. Buy Levaquin (Levofloxacin) with free prescription The major biologics used for treating colorectal cancer include Erbitux (cetuximab), Zaltrap (ziv-Aflibercept), Avastin (bevacizumab), and Vectibix (panitumumab). About Female Viagra (Sildenafil Citrate) with free prescription These biologics together accounted for the major share of the market, and the same trend is expected to continue during the forecast period. According to the report, colorectal cancers cannot be cured by the currently available therapeutic options. About Ditropan In addition, if it has not metastasized, surgery would be the only option. About Thorazine (Chlorpromazine) without Rx The chances of cancer recurring near the place of origin are high. Buy Vitamin B2 - Riboflavin online The currently available branded and generic drugs are indicated only for off-label treatment use. http://medical-reviews.blogspot.com However, these drugs have many side effects. Hyperbilirubinemia, gastrointestinal perforation, coagulopathy, cardiotoxicity, hemorrhage, hepatotoxicity, neutropenia, proteinuria, thrombocytopenia, ischemia, soft tissue toxicity, pulmonary fibrosis, and increased mortality are some of the significant adverse side effects. Thus, a drug maker has opportunities to exploit and seek a favorable position in the market by addressing these issues. Further, the report states that many branded drugs available in the market have lost their patents or are expected to lose it during the forecast period. This report covers the present scenario and the growth prospects of the global colorectal cancer drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of colorectal cancer. Based on the type of molecule, the market is grouped into two categories: - Biologics - Small molecules Based on the route of administration, the market is grouped into two categories: - Oral - Parenteral Key Vendors - Amgen - Bayer - Bristol-Myers Squibb - F. Hoffmann-La Roche - Merck Serono Other Prominent Vendors - Accord Healthcare - Advenchen Laboratories - Aeterna Zentaris - AstraZeneca - Bavarian Nordic - Biothera - Boehringer Ingelheim - Daiichi Sankyo - Debiopharm - Eisai - Eli Lilly - Immodulon Therapeutics - Mologen - Mylan - Nektar Therapeutics - Oncothyreon - Otsuka Pharmaceutical - Precision Biologics - Sun Pharmaceutical - Symphogen - Taiho - Takeda - Teva - ThromboGenics - Xbiotech - Yakult Honsha For more information visit .researchandmarkets.com/research/p8l4hh/global_colorectal

Takeda pr'esente un dossier d'autorisation de mise sur le march'e pour l'ixazomib en vue du traitement des patients atteints de my'elome multiple r'ecurrent ou r'efractaire aux m'edicaments

CAMBRIDGE, Massachusetts et OSAKA, Japon--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (Bourse de Tokyo : 4502) a annonc e aujourd hui qu elle avait pr esent e `a la Food and Drug Administration (FDA) des Etats-Unis un dossier d autorisation de mise sur le march e pour l ixazomib, un inhibiteur oral exp erimental du prot easome, en vue du traitement des patients atteints de my elome multiple r ecurrent ou r efractaire aux m edicaments. Le dossier d autorisation de mise sur le march e se fonde sur l etude clinique de phase III TOURMALINE-MM1, un essai clinique international, randomis e, `a double insu, contr^ol e par placebo, men e aupr`es de 722 patients dans le but d evaluer la sup eriorit e de l ixazomib en association avec le l enalidomide et la dexam ethasone sur un placebo en association avec le l enalidomide et la dexam ethasone chez des patients adultes atteints de my elome multiple r ecurrent et/ou r efractaire. About Indocin Sr (Indomethacin) without Rx Durant l essai clinique, les patients poursuivent leur traitement et les r esultats `a long terme sont evalu es. « L etude TOURMALINE-MM1 est la premi`ere d une s erie de cinq essais cliniques de phase III faisant partie de notre programme sur l ixazomib, lequel a pour but d evaluer si un traitement prolong e par un inhibiteur du prot easome, par voie orale, am eliore les r esultats cliniques des patients atteints de my elome multiple ou d amylose A, a d eclar e Andrew Plump, M.D., Ph. About Nizoral Cream (Ketoconazole) with free prescription D., m edecin-chef et conseiller scientifique en chef de Takeda. About Viagra Soft (Sildenafil Citrate) with free Rx Cette pr esentation t emoigne de l engagement continu de Takeda `a innover au service des patients atteints de my elome multiple. About Detrol with free prescription Nous remercions les patients et leur famille de la confiance qu ils accordent `a Takeda et `a l ixazomib en participant au programme TOURMALINE. Vitamin B12 (Methylcobalamin) with no Rx » « La continuit e du traitement chez les patients atteints de my elome multiple est maintenant accept ee comme norme de traitement etant donn e l am elioration des r esultats `a long terme, a fait remarqu e Paul Richardson, M.D., directeur du programme clinique et directeur de la recherche, Jerome Lipper Multiple Myeloma Center, m edecin au Dana-Farber Cancer Institute. Buy Stevia online L inhibition du prot easome est devenue une composante essentielle du traitement, mais les approches intraveineuses et sous-cutan ees posent des probl`emes d ordre logistique aux patients, en particulier en l absence d option orale efficace. http://webmdhelper.wordpress.com S il est approuv e, l ixazomib devrait repr esenter une avanc ee significative pour nos patients, etant donn e son efficacit e et la commodit e d une administration orale hebdomadaire. » Il s agit de la premi`ere pr esentation r eglementaire concernant l ixazomib. D autres dossiers seront d epos es en Europe et dans d autres pays plus tard cette ann ee. `A propos du my elome multipleLe my elome multiple est un cancer du sang qui se d eclare dans la moelle osseuse. La maladie se caract erise par la prolif eration de cellules plasmatiques anormales. Parce les cellules plasmatiques circulent largement dans le corps, elles peuvent affecter de nombreux os et entra^iner des fractures par tassement, des l esions osseuses lytiques et de la douleur. Le my elome multiple peut entra^iner nombre de graves probl`emes de sant e touchant les os, le syst`eme immunitaire, les reins et le nombre de globules rouges dans le sang, les sympt^omes les plus courants etant notamment des douleurs aux os et de la fatigue, un signe d an emie. Le my elome multiple est une forme de cancer relativement rare. Chaque ann ee, environ 20 000 nouveaux cas sont d eclar es aux Etats-Unis et il y a 114 000 nouveaux cas `a l echelle mondiale. `A propos de l ixazomibL’ixazomib (MLN9708) est un inhibiteur oral exp erimental du prot easome `a l etude dans le traitement du my elome multiple, de l’amylose AL et d autres affections malignes. L’ixazomib a recu la d esignation de m edicament orphelin pour le my elome multiple aux Etats-Unis et en Europe en 2011, et pour l’amylose AL aux Etats-Unis et en Europe en 2012. En 2014, la Food and Drug Administration (FDA) des Etats-Unis a accord e `a l’ixazomib la d esignation « th erapie r evolutionnaire » pour les patients atteints d amylose AL r ecurrente ou r efractaire. Il s’agit egalement du premier inhibiteur oral du prot easome `a faire l objet d essais cliniques de phase III. Le programme de d eveloppement clinique de l ixazomib souligne l engagement constant de Takeda `a mettre au point des m edicaments novateurs au profit des personnes souffrant de my elome multiple dans le monde entier et des professionnels de la sant e qui participent `a leur traitement. Cinq essais mondiaux de phase III sont en cours : TOURMALINE-MM1, qui etudie l’ixazomib comparativement au placebo en association avec le l enalidomide et la dexam ethasone pour le my elome multiple r ecurrent et/ou r efractaire TOURMALINE-MM2, qui etudie l’ixazomib comparativement au placebo en association avec le l enalidomide et la dexam ethasone chez des patients atteints d un my elome multiple nouvellement diagnostiqu e TOURMALINE-MM3, qui etudie l’ixazomib comparativement au placebo comme traitement d entretien chez des patients atteints d un my elome multiple nouvellement diagnostiqu e apr`es un premier traitement et une greffe de cellules souches autologue TOURMALINE-MM4, qui etudie l’ixazomib comparativement au placebo comme traitement d entretien chez des patients atteints d un my elome multiple nouvellement diagnostiqu e qui n ont pas subi de greffe de cellules souches autologue TOURMALINE-AL1, qui etudie l’ixazomib en association avec la dexam ethasone comparativement `a une s election de sch emas th erapeutiques au choix du m edecin chez des patients ayant une amylose AL r ecurrente ou r efractaire Pour en apprendre plus sur les etudes de phase III en cours, visitez le site .clinicaltrials.gov. `A propos de Takeda OncologyTakeda Oncology est une unit e commerciale d envergure mondiale de Millennium Pharmaceuticals inc., une filiale en propri et e exclusive de Takeda Pharmaceutical Company Limited. Takeda aspire `a gu erir le cancer en mettant au point de nouveaux m edicaments afin de r epondre aux besoins uniques et pressants des personnes atteintes d un cancer, de leurs proches et des fournisseurs de soins de sant e dans le monde entier. Takeda arrive au 11e rang mondial des soci et es pharmaceutiques sp ecialis ees en oncologie. Elle compte un portefeuille de m edicaments aptes `a modifier les paradigmes de traitement et plusieurs produits exp erimentaux qui ont le potentiel d am eliorer consid erablement les r esultats des patients atteints de diff erents cancers. En alliant le pouvoir de la recherche scientifique `a l esprit d entreprise et aux vastes ressources d une soci et e pharmaceutique mondiale, Takeda Oncology trouve des facons nouvelles et novatrices d am eliorer le traitement du cancer. Pour obtenir de plus amples renseignements sur Takeda Oncology, consultez son site Web `a l adresse .takedaoncology.com. `A propos de TakedaTakeda est une soci et e pharmaceutique d envergure mondiale ax ee sur la recherche. Son si`ege social est situ e `a Osaka, au Japon. La plus grande soci et e pharmaceutique au Japon et un des leaders mondiaux dans son secteur, Takeda concentre ses efforts sur l am elioration de la sant e des patients `a travers le monde au moyen d innovations m edicales de premier plan. Pour de plus amples renseignements sur Takeda, consultez le site Web de la soci et e `a l adresse .takeda.com. Le texte du communiqu e issu d’une traduction ne doit d’aucune mani`ere ^etre consid er e comme officiel. La seule version du communiqu e qui fasse foi est celle du communiqu e dans sa langue d’origine. La traduction devra toujours ^etre confront ee au texte source, qui fera jurisprudence.